Antiplatelet Agents for Cancer Prevention: Current Evidences and Continuing Controversies.

ABSTRACT: Over the past two decades, aspirin has emerged as a promising chemoprotective agent to prevent colorectal cancer (CRC). In 2016, the mounting evidence supporting its chemoprotective effect, from both basic science and clinical research, led the US Preventive Services Task Force to recommend regular use of low-dose aspirin in some subgroups of patients for whom the benefits are deemed to outweigh the risks. In contrast, data on the chemoprotective effect of aspirin against other cancers are less clear and remain controversial. Most data come from secondary analyses of cardiovascular prevention trials, with only a limited number reporting cancer outcomes as a prespecified endpoint, and overall unclear findings. Moreover, the potential chemoprotective effect of aspirin against other cancers h

SUBMITTER: Frere C 

PROVIDER: S-EPMC6895806 | biostudies-literature | 2019 Oct

REPOSITORIES: biostudies-literature